About: Abstract Against the backdrop of the Covid pandemic, the scientific and medical communities are working with all deliberate speed with state-of-the-art technologies to develop diagnostic and therapeutic products that can identify, treat and prevent SARS-CoV-2. This can only happen with the necessary statutes and regulations in place to facilitate the timely development, manufacturing, evaluation, and distribution of products that meet quality standards. The present regulatory landscape for medicinal and medical products for human use has been shaped by nearly twelve decades of statutory history that followed in reaction to disasters and tragedies. Five distinct, closely woven threads of developments have led to the regulatory infrastructure we have in place: (1) Regularized processes for routine development of medicinal and medical products for human use; (2) Expedited development processes to shorten time frames and expand patient populations; (3) Expanded Access mechanisms to make medicinal products available to patients prior to FDA approval; (4) Emergency Use Authorization during public health emergencies; and (5) the development of the generic drug and biosimilar biologics pathways to market. These mechanisms are being brought to bear to facilitate the defeat SARS-CoV-2.   Goto Sponge  NotDistinct  Permalink

An Entity of Type : fabio:Abstract, within Data Space : covidontheweb.inria.fr associated with source document(s)

AttributesValues
type
value
  • Abstract Against the backdrop of the Covid pandemic, the scientific and medical communities are working with all deliberate speed with state-of-the-art technologies to develop diagnostic and therapeutic products that can identify, treat and prevent SARS-CoV-2. This can only happen with the necessary statutes and regulations in place to facilitate the timely development, manufacturing, evaluation, and distribution of products that meet quality standards. The present regulatory landscape for medicinal and medical products for human use has been shaped by nearly twelve decades of statutory history that followed in reaction to disasters and tragedies. Five distinct, closely woven threads of developments have led to the regulatory infrastructure we have in place: (1) Regularized processes for routine development of medicinal and medical products for human use; (2) Expedited development processes to shorten time frames and expand patient populations; (3) Expanded Access mechanisms to make medicinal products available to patients prior to FDA approval; (4) Emergency Use Authorization during public health emergencies; and (5) the development of the generic drug and biosimilar biologics pathways to market. These mechanisms are being brought to bear to facilitate the defeat SARS-CoV-2.
Subject
  • Drugs
  • Pharmacy
  • Life sciences industry
  • Patent law
  • Pharmaceutical industry
  • Statistical process control
part of
is abstract of
is hasSource of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software